Sam Brusco, Associate Editor08.28.23
RQM+, a medtech service provider, has acquired CRO Kottmann, a German contract research organization (CRO) known for customer service, scientific clinical research, and quality.
Integrating CRO Kottmann, according to RQM+, enhances the company’s geographic footprint and comprehensive, end-to-end client support from preclinical phases to commercialization. The company expands RQM+’s business as a medtech CRO.
Kottmann conducts clinical studies with medical devices, in-vitro diagnostics, and pharmaceuticals. In addition to full-service, the company offers creation of databases (eCRFs), statistical evaluations, and clinical monitoring for studies.
“We are tremendously excited about this pivotal acquisition. The synergy between RQM+ and CRO Kottmann will propel us to greater heights in the industry. The German market, well known for its emphasis on science, innovation, and market intelligence, is a vital geography for RQM+,” RQM+ CEO of Clinical Trial Services, David Novotny told the press. “With the combined expertise of both organizations, we will achieve quicker, more efficient operational deliveries that will facilitate a faster market entry for our clients.”
The company said CRO Kottmann adds a combination of regulatory and clinical experience, new capabilities, and further geographical reach.
“We have always held a like-minded approach to ensuring best-in-class customer service and advisement. This alignment of core values, coupled with our shared ambition to foster growth in science and innovation, will make this partnership a continuation of the success story in Clinical Research. We are pleased to be able to offer our clients an even greater depth of clinical research services. Going forward, our clients can continue using our services to conduct global studies worldwide,” said Tanja Kottmann MD, CEO of CRO Kottmann.
Last week, RQM+ launched its Fern.ai human-in-the-loop artificial intelligence (AI) platform to standardize clinical evidence literature review.
Integrating CRO Kottmann, according to RQM+, enhances the company’s geographic footprint and comprehensive, end-to-end client support from preclinical phases to commercialization. The company expands RQM+’s business as a medtech CRO.
Kottmann conducts clinical studies with medical devices, in-vitro diagnostics, and pharmaceuticals. In addition to full-service, the company offers creation of databases (eCRFs), statistical evaluations, and clinical monitoring for studies.
“We are tremendously excited about this pivotal acquisition. The synergy between RQM+ and CRO Kottmann will propel us to greater heights in the industry. The German market, well known for its emphasis on science, innovation, and market intelligence, is a vital geography for RQM+,” RQM+ CEO of Clinical Trial Services, David Novotny told the press. “With the combined expertise of both organizations, we will achieve quicker, more efficient operational deliveries that will facilitate a faster market entry for our clients.”
The company said CRO Kottmann adds a combination of regulatory and clinical experience, new capabilities, and further geographical reach.
“We have always held a like-minded approach to ensuring best-in-class customer service and advisement. This alignment of core values, coupled with our shared ambition to foster growth in science and innovation, will make this partnership a continuation of the success story in Clinical Research. We are pleased to be able to offer our clients an even greater depth of clinical research services. Going forward, our clients can continue using our services to conduct global studies worldwide,” said Tanja Kottmann MD, CEO of CRO Kottmann.
Last week, RQM+ launched its Fern.ai human-in-the-loop artificial intelligence (AI) platform to standardize clinical evidence literature review.